98%
921
2 minutes
20
Context: Time-limited trials (TLTs) are a collaborative plan among clinicians, patients, and surrogates to use life-sustaining therapy for a defined duration, after which the response to therapy informs the decision to either continue care focused on recovery or transition to comfort-focused care.
Objectives: To evaluate 1) how often goals of care (GOC) notes document TLT use; 2) what patient and clinician characteristics are associated with documented TLTs; and 3) how TLTs are described in GOC documentation.
Methods: We conducted a retrospective cross-sectional study of documented standardized GOC template notes for seriously ill hospitalized adult patients across 21-hospitals between 2021 and 2023. We evaluated notes using descriptive statistics paired with qualitative, directed content analysis.
Results: Of 5475 GOC-template notes, we found reference to a TLT in 1% (n = 69/5475). Patients with TLT documentation were younger (72 vs 76 years, P = 0.0221), more likely to be self-pay or uninsured (7% vs. 2%, P = 0.0309), more likely to die in the hospital (54% vs. 27%, P < 0.0001) or discharge to a long-term acute care hospital (15% vs. 1%, P < 0.0001), when compared to patients with no such documentation. Notes with TLT documentation were more likely to document patient prognosis (94% vs. 79%, P = 0.0009) and less likely to document an accompanying change in patient code status (22% vs. 36%, P = 0.0117).
Conclusions: TLTs are rarely documented within a standardized GOC note for seriously ill patients. Future research is needed to identify and address reasons for low documentation of TLTs in the EHR.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363427 | PMC |
http://dx.doi.org/10.1016/j.jpainsymman.2025.04.007 | DOI Listing |
Med Klin Intensivmed Notfmed
September 2025
PalliativCentrum und Medizinische Klinik I, Universitätsklinikum Carl Gustav Carus Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland.
Intensive care for patients with hemato-oncological diseases is a complex interplay between life-prolonging therapy and palliative care. Especially in cases with a limited prognosis, early clarification of treatment goals and transition to palliative-oriented measures become increasingly important. When is a change in treatment goals appropriate in the intensive care unit, and how can patient-centered, suffering-oriented care be implemented in a structured way? The concept of a time-limited trial (TLT) offers a structured framework to allow a limited period of intensive care treatment with clearly defined success criteria in cases of uncertain prognosis.
View Article and Find Full Text PDFHealth Expect
October 2025
Division of Neuroscience, School of Medicine and Population Health, Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.
Objective: To explore intervention fidelity and experiences of using a new intervention designed to optimise calorie intake in people with amyotrophic lateral sclerosis (ALS).
Methods: A mixed-methods process evaluation was conducted alongside an ongoing randomised controlled trial across 15 ALS specialist centres in the United Kingdom. Data collection included 146 healthcare professional-completed fidelity checklists, audio recordings of 5 intervention sessions, and qualitative interviews with 32 healthcare professionals, patients and informal caregivers.
Vaccine
August 2025
Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Selangor, Malaysia.
Background: The emergence of new COVID-19 variants necessitates continuous evaluation of vaccine effectiveness to guide evolving vaccine strategies. This study assessed the relative effectiveness of a fourth COVID-19 vaccine dose compared to a third dose in Malaysia during the Omicron BA.4/BA.
View Article and Find Full Text PDFCrit Care Explor
August 2025
Medical Intensive Care Unit, Nantes University Hospital, Nantes, France.
Importance: The occurrence of death shortly after ICU admission raises concerns about the appropriateness of providing intensive care to frail patients-many of whom are subsequently subject to decisions to limit life-supporting treatment limitation (LST-L). The proportion of patients who die early and are affected by such limitations remains unknown.
Objectives: The primary objective was to determine the proportion of patients with a decision of LST-L among patients who died within 48 hours after ICU admission.
Hematol Oncol Clin North Am
July 2025
Haematological Malignancy Diagnostic Service (HMDS), Level 3, Bexley Wing, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK; Department of Epidemiology and Cancer Statistics (ECSG), University of York, Seebohm Rowntree Building, York, YO10 5DD, UK. Electronic address: andy.rawstron
Minimal residual disease (MRD) testing has become a central response biomarker in clinical trials of time-limited treatment, with MRD-guided strategies under increasing evaluation. This article compares key technical and practical features of available MRD approaches and provides guidance on selecting the appropriate method and threshold for varied clinical applications.
View Article and Find Full Text PDF